Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Safety and Performance of the HARMONI® Toric Lens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03050697
Recruitment Status : Completed
First Posted : February 13, 2017
Results First Posted : June 11, 2020
Last Update Posted : June 12, 2020
Sponsor:
Information provided by (Responsible Party):
ClarVista Medical

Brief Summary:
The purpose of this study was to evaluate the safety and effectiveness of the HARMONI® Modular Intraocular Lens System with a toric optic (HMTIOL) in subjects with pre-existing corneal astigmatism in need of cataract surgery.

Condition or disease Intervention/treatment Phase
Aphakia Corneal Astigmatism Cataract Device: HARMONI® Modular Toric Intraocular Lens Procedure: Cataract extraction with intraocular lens (IOL) implantation Not Applicable

Detailed Description:

Subjects with visually significant bilateral cataracts (cortical, nuclear, posterior subcapsular, or a combination) were implanted unilaterally (in one eye only) or bilaterally (in both eyes) with the HMTIOL. A total of 7 study visits were planned, including a preoperative visit, operative visits for each eye, and 4 follow-up visits at 1 day, 1 week, 1 month, and 3 months postoperative. The total duration of participation for each subject was up to 6 months, including the preoperative period (up to 3 months).

Alcon Research, LLC, acquired ClarVista Medical in 2017. This study was designed and conducted by ClarVista Medical, Inc. The study results were collected, analyzed, and provided by ClarVista Medical, Inc. to Alcon Research, LLC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter Study to Evaluate the Safety and Performance of the Exchangeable ClarVista HARMONI Modular Toric Intraocular Lens System for the Treatment of Pre-Existing Corneal Astigmatism and Aphakia Following Cataract Surgery
Actual Study Start Date : September 28, 2016
Actual Primary Completion Date : June 7, 2017
Actual Study Completion Date : July 28, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: HMTIOL
HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
Device: HARMONI® Modular Toric Intraocular Lens
Two-component system consisting of a base and a separate toric optic
Other Name: HMTIOL

Procedure: Cataract extraction with intraocular lens (IOL) implantation
Cataract removal via manual phacoemulsification, followed by HMTIOL implantation




Primary Outcome Measures :
  1. Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL [ Time Frame: Month 1 postoperative, Month 3 postoperative ]
    A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of added correction needed to compensate for any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number, with a less negative number indicating a lesser amount of added correction. No formal statistical hypothesis testing was planned.

  2. Mean Manifest Refraction Cylinder (MRCYL) Prediction Error (PE) for Eyes Implanted With HMTIOL [ Time Frame: Month 1 postoperative, Month 3 postoperative ]
    A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. MRCYL PE was calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.

  3. MRCYL PE for Eyes Implanted With HMTIOL Per Vector Analyses [ Time Frame: Month 1 postoperative, Month 3 postoperative ]
    Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL PE is calculated as postoperative MRCYL adjusted to 6 meters minus MRCYL target residual refractive error (TRRE), with a lower absolute value indicating a more accurate cylinder power calculation. No formal statistical hypothesis testing was planned.

  4. Mean Reduction in Cylinder Power for Eyes Implanted With HMTIOL [ Time Frame: Baseline (Day 0 preoperative), Month 3 postoperative ]
    A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. No formal statistical hypothesis testing was planned.

  5. Mean Percent Reduction in Cylinder Power for Eyes Implanted With HMTIOL [ Time Frame: Baseline (Day 0 preoperative), Month 3 postoperative ]
    A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. Manifest refraction cylinder is the amount of power needed to correct any astigmatism that may be present. MRCYL was measured in diopters and reported as a negative number. Cylinder power reduction was calculated as the absolute preoperative magnitude of corneal cylinder (K) minus the absolute postoperative magnitude of MRCYL at the corneal plane. Therefore, the cylindrical power percent reduction was the cylinder power reduction divided by the absolute value of preoperative magnitude of corneal cylinder (K) × 100. A higher number (greater percent reduction) indicates better astigmatism correction by the toric IOL. No formal statistical hypothesis testing was planned.

  6. Mean Manifest Refraction Spherical Equivalent (MRSE) Prediction Error (PE) [ Time Frame: Month 1 postoperative, Month 3 postoperative ]
    A manifest refraction (manual vision test) was conducted using letter charts and a phoropter. The manifest refraction spherical equivalent (MRSE) was calculated as follows: sphere + 1/2 cylinder, and measured in diopters (D). MRSE PE was calculated as postoperative MRSE adjusted to 6 meters minus MRSE target residual refractive error (TRRE). The lower the absolute number, the more accurate the IOL power calculation is. No formal statistical hypothesis testing was planned.

  7. Mean Absolute Misalignment of IOL Meridian - Target Versus Actual at Operative Visit [ Time Frame: Day 0 (operative) ]
    Absolute misalignment of IOL meridian was defined as the summation of IOL misplacement and IOL rotation. A lower number indicates minimal IOL misalignment. No formal statistical hypothesis testing was planned.

  8. Mean Absolute Rotation of IOL Meridian by Visit [ Time Frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative ]
    IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees. No formal statistical hypothesis testing was planned.

  9. Number of Eyes With Absolute Rotation of IOL Meridian by Visit [ Time Frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative ]
    IOL orientation was measured with slit-lamp photography. IOL rotation was defined as the difference between axis of IOL orientation on the day of surgery and the subsequent postoperative visit. IOL rotation was measured in degrees and is reported categorically. No formal statistical hypothesis testing was planned.

  10. Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) by Visit [ Time Frame: Baseline (Day 0 preoperative), Week 1 postoperative, Month 1 postoperative, Month 3 postoperative ]
    Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with the correction obtained from manifest refraction testing. BCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.

  11. Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit [ Time Frame: Baseline (Day 0 preoperative), Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative ]
    Visual Acuity of the eye was tested while reading charts at 20-foot equivalent distance from the participant with an optical infinity adjustment of +0.25 diopter (D). UCDVA is reported categorically using the Snellen fraction, which compares the participant's result to the result expected from a 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity. No formal statistical hypothesis testing was planned.

  12. Standard Error of the Mean in Lens Power A-constant for Refinement [ Time Frame: Day 0 operative ]

    The A-constant (lens power constant) is a theoretical value that is used to calculate the power of the intraocular lens. It relates the lens power to the eye's axial length and keratometry. It is not expressed in units; it is specific to the design of the IOL and its intended location and orientation within the eye.

    A-constants are typically empirically developed for new IOLs based on hundreds of clinical uses. Data from a sufficient number of eyes are needed in order to reduce bias due to surgical technique, unusual eyes, and differences in equipment, such that the standard error of the mean in the lens power constant would be less than ±0.10 mm (approximately ±0.2 diopter). This study represented the first clinical use of the HMTIOL.


  13. Number of Ocular Adverse Events Through Month 3 [ Time Frame: Up to Month 3 postoperative ]
    Ocular adverse events were identified as outlined in ISO 11979-2014 Annex B. No formal statistical hypothesis testing was planned.

  14. Number of Device-Related Secondary Surgical Interventions (SSI) Other Than Optic Exchange and Rotational Adjustment of the HMTIOL [ Time Frame: Up to Month 3 postoperative ]
    A secondary surgical intervention (SSI) was defined as a surgical procedure that occurred after primary implantation and was conducted for the purpose of resolving residual refractive error (RRE) and optimizing visual outcomes. No formal statistical hypothesis testing was planned.

  15. Number of Device Deficiencies Post Implantation [ Time Frame: Up to Month 3 postoperative ]
    A device deficiency was defined as a failure of the device to meet its performance specifications or expectations, or otherwise not perform as intended. This could include either a malfunction or damage to the device or any part thereof, regardless of the source of malfunction or damage, including user error, and regardless of the presence of injury (or lack thereof) to subject, user, or bystander. No formal statistical hypothesis testing was planned.

  16. Number of Eyes With Preservation of Best Corrected Distance Visual Acuity (BCDVA) at Month 1 and Month 3 [ Time Frame: Month 1 postoperative, Month 3 postoperative ]
    Preservation of BCDVA was defined in terms of lines lost when reading the ETDRS chart at each visit compared to the prior best-achieved BCDVA. Loss of < 1 line included subjects with less than a 1 line loss, no change or improvement in BCDVA. No formal statistical hypothesis testing was planned.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Planned removal of visually significant bilateral cataract by manual phacoemulsification cataract extraction
  • Pre-existing corneal astigmatism in at least 1 eye of 0.75 to 2.50 diopter (D)
  • Target dioptric lens power within the range of 16 - 26 D
  • Willing to discontinue contact lens wear for the duration of the study
  • BCVA projected to be ≤0.2 logarithm minimum angle of resolution (LogMAR)
  • Stable cornea
  • Dilated pupil size at least 7.0 millimeters (mm)
  • Able to understand and provide informed consent.

Key Exclusion Criteria:

  • History of any intraocular or corneal surgery in study eye (including refractive)
  • Pregnant or lactating
  • History of any clinically significant retinal pathology or ocular diagnosis in study eye that could alter or limit final postoperative visual prognosis
  • History of ocular conditions which could affect the stability of the IOL in study eye
  • Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction in study eye
  • Any visually significant intraocular media opacity other than cataract in study eye
  • Uncontrolled glaucoma in study eye
  • Uncontrolled systemic disease
  • Severe dry eye that would impair the ability to obtain reliable study measurements
  • Systemic medication that may confound the outcome or increase the intraoperative and postoperative risk to the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050697


Locations
Layout table for location information
New Zealand
ClarVista Investigative Site
Auckland, New Zealand, 99311
Sponsors and Collaborators
ClarVista Medical
Investigators
Layout table for investigator information
Study Director: Sr. Clinical Trial Lead, CDMA Surgical Alcon Research, LLC
  Study Documents (Full-Text)

Documents provided by ClarVista Medical:
Study Protocol  [PDF] June 6, 2016
Statistical Analysis Plan  [PDF] June 29, 2017

Layout table for additonal information
Responsible Party: ClarVista Medical
ClinicalTrials.gov Identifier: NCT03050697    
Other Study ID Numbers: CP-00004
First Posted: February 13, 2017    Key Record Dates
Results First Posted: June 11, 2020
Last Update Posted: June 12, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by ClarVista Medical:
Toric
Intraocular lens
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Astigmatism
Aphakia
Lens Diseases
Eye Diseases
Refractive Errors